PPD, angling to stand out among CROs running pediatric trials, has cemented a network of 8 global sites to accelerate the process of starting studies on kids.
The idea, according to PPD, is to offer sponsors a predictable, scalable model for pediatric trials of all sizes, smoothing out the thorny early stages of planning a study. Having a go-to network of trusted sites allows for quick preparations, easier enrollment and, ultimately, higher-quality data, according to the company.
The 8-center network includes Columbia University, Seattle Children's Research Institute, Schneider Children's Medical Center of Israel and a pair of National Health Service centers in the U.K.
Drug developers and global regulators are increasingly recognizing the importance of running pediatric trials on in-development products, especially in rare diseases, and PPD believes its efforts make it a leader among CROs in the field.
"Our network already has been working effectively with our clients to provide state-of-the-art clinical trial delivery across the globe," Dr. Mark Sorrentino, PPD executive medical director, said in a statement. "Building formal relationships with strategically important centers that have significant pediatric clinical trial expertise, a proven track record of superior quality and the ability to recruit pediatric patients demonstrates our commitment to partnering with our clients to bring life-changing medications to market faster and at less cost."
PPD is plotting to expand its network over the coming years, working to recruit new centers of excellence.
- read the statement